Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS
(MedPage Today) -- Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic cell transplantation (HCT) improved outcomes for patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Hematology | Leukemia | Myelodysplastic Syndrome | Transplants